C16

• Background:

  C16 is a derivative of imidazolo-oxindole and inhibits RNA-dependent protein kinases (PKR). Its inhibition effect on PKR is ATP-binding site directed. C16 has been shown to specifically inhibit the apoptotic PKR/eIF2a signaling pathway.

• Description:

  PKR kinase inhibitor

• Product Name Alternative:

  Imidazolo-oxindole PKR inhibitor C16, 6,8-Dihydro-8- (1H-imidazol-5-ylmethylene) -7H-pyrrolo[2,3-g]benzothiazol-7-one

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

• Purity:

  ≥98% (HPLC)

• Weight:

  0.025

• Format:

  Solid

• Solubility:

  Soluble in DMSO 12 mg/ml

• Molecular Formula:

  C13H8N4OS

• Molecular Weight:

  268.3

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Couturier J., et al. (2010) J. Biol. Chem. 285(2): 1272–1282. 2. Jammi N.V., Whitby L.R., & Beal P.A. (2003) Biochem. Biophys.Res. Comm. 308(1):50–57.

• CAS Number:

  608512-97-6